Related Experiment Video
Updated: Jan 4, 2026

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
Published on: March 29, 2024
Liver disease and heart failure
Michele Correale1, Lucia Tricarico2, Alessandra Leopizzi2
1Unit of Cardiology, Ospedali Riuniti University Hospital of Foggia, Foggia, Italy - opsfco@tin.it.
Insights
Liver and heart conditions often coexist due to systemic diseases. Early assessment of liver function tests (LFTs) in acute decompensated heart failure (ADHF) is crucial for effective patient management and improved outcomes.
Area of Science:
- Cardiology
- Hepatology
- Internal Medicine
Background:
- Systemic conditions like inflammatory diseases, infections, alcoholism, and non-alcoholic fatty liver disease (NAFLD) can impact both cardiac and hepatic function.
- Acute decompensated heart failure (ADHF) can lead to acute ischemic hepatitis, while chronic heart failure (HF) may result in congestive hepatopathy (CH).
Purpose of the Study:
- To emphasize the importance of evaluating both cardiac and hepatic function in patients with advanced HF.
- To highlight the predictive value of hepatic function tests (LFTs) for patient outcomes.
Main Methods:
- Review of clinical presentations and laboratory findings in patients with coexisting heart and liver conditions.
- Analysis of how abnormal LFTs indicate specific mechanisms of liver injury (congestion or ischemia).
Main Results:
- Abnormal LFTs can signify liver congestion or ischemia, guiding treatment decisions in acute heart failure (AHF).
- Right-sided HF is present in over 90% of patients with clinically apparent ischemic hepatitis.
- Systemic disorders affecting metal accumulation or metabolism can lead to hypertrophic cardiomyopathy (HCM) and liver issues.
Conclusions:
- Liver function tests (LFTs) are recommended in the early management of ADHF.
- Physicians, particularly cardiologists and internists, need training in evaluating LFTs and recognizing systemic diseases affecting both heart and liver.
- Early identification of signs and symptoms of rare diseases and liver conditions that may mimic HF is critical for accurate diagnosis and treatment.
Introduction:
Several systemic conditions, inflammatory disease, infections and alcoholism, may affect both the heart and the liver. Common conditions, such as the non-alcoholic fatty liver disease (NAFLD), may increase the risk of cardiac dysfunction. Patients with acute decompensated HF (ADHF) may develop acute ischemic hepatitis and, chronic HF patients may develop congestive hepatopathy (CH).
Evidence Acquisition:
Laboratory anomalies of hepatic function may predict the outcome of patients with advanced HF and the evaluation of both cardiac and hepatic function is very important in the management of these patients. In clinically apparent ischemic hepatitis more than 90% of patients have some right-sided HF. There are systemic disorders characterized by the accumulation of metals or by metabolism defects that may affect primarily the liver but also the heart leading to symptomatic hypertrophic cardiomyopathy (HCM).
Evidence Synthesis:
Abnormal LFTs indicate the mechanism of liver injury: liver congestion or liver ischemia. In AHF, it's important an adequate evaluation of heart and liver function in order to choose the treatment in order to ensure stable hemodynamic as well as optimal liver function.
Conclusions:
Measurements of LFTs should be recommended in the early phase of ADHF management. Physicians with interest in HF should be trained in the evaluation of LFTs. It's very important for cardiologists to know the systemic diseases affecting both heart and liver and the first imaging or laboratory findings useful for a diagnosis. it is very important for internists, nephrologists, cardiologists, primary physicians and any physicians with interest in treating HF to recognize such signs and symptoms belong to rare diseases and liver diseases that could be mistaken for HF.
More Related Videos
04:49Author Spotlight: Investigating the Underlying Mechanisms of Right Ventricular Failure in Pulmonary Hypertension
Published on: June 14, 2024
08:41Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
Published on: March 24, 2023
Related Concept Videos
Heart Failure I: Introduction
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Pathophysiology of Heart Failure
Heart Failure Drugs: Diuretics
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Heart Failure III: Clinical Manifestations